| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
3-Hydroxypyridine targets DNA topoisomerase 2-beta (Topo IIβ), inhibiting its activity. It also exhibits inhibitory activity against HIV-1 replication in Sup-T1 cells. As an endogenous photosensitizer, 3-hydroxypyridine can mediate oxidative stress, proliferation inhibition, and apoptosis of skin cells through UVA/UVB excitation. It exhibits diverse pharmacological properties, including antioxidant activity.
|
|---|---|
| ln Vitro |
In vitro, 3-hydroxypyridine exhibits inhibitory activity against DNA topoisomerase 2-beta (Topo IIβ) and HIV-1 replication in Sup-T1 cells. As an endogenous photosensitizer, it can mediate oxidative stress, proliferation inhibition, and apoptosis of skin cells through UVA/UVB excitation. 3-Hydroxypyridine (100 µM; 3 days) inhibits proliferation and induces cell cycle arrest and apoptosis in HaCaT keratinocytes after solar simulated light irradiation.
|
| ln Vivo |
3-Hydroxypyridine is not a pharmacologically approved drug. It is a naturally occurring compound that has been studied for its potential in photodynamic therapy and antiviral applications. As an endogenous photosensitizer, it has been investigated for its role in skin cell responses to UV radiation. The compound has not been evaluated in clinical trials and is not approved for therapeutic use.
|
| Enzyme Assay |
In vitro assays for 3-hydroxypyridine typically involve cell viability, proliferation, and apoptosis studies. A standard protocol involves culturing HaCaT keratinocytes in 96-well plates and treating them with varying concentrations of 3-hydroxypyridine (typically 1-100 µM) for 3 days. Cell viability is assessed using MTT assays. Cell cycle analysis is performed by flow cytometry after propidium iodide staining. Apoptosis is measured using Annexin V/PI staining.
|
| Cell Assay |
In vitro cell culture experiments with 3-hydroxypyridine typically involve HaCaT keratinocytes or Sup-T1 cells. Cells are cultured in appropriate media and treated with the compound at concentrations ranging from 1-100 µM for 1-3 days. Cell viability is assessed using MTT assays. Apoptosis is measured using Annexin V/PI staining or caspase activity assays. For photosensitizer studies, cells are irradiated with UVA/UVB light after treatment.
|
| Animal Protocol |
In vivo animal studies with 3-hydroxypyridine are not well documented, as it is primarily a research compound. If conducted, typical protocols for photodynamic therapy studies would involve administering the compound topically or systemically to animals followed by light irradiation. However, such studies are not standard for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 3-hydroxypyridine are not characterized, as it is not a drug substance. Based on its physicochemical properties (molecular weight 95.10, moderate water solubility), the compound would be expected to have moderate oral bioavailability. However, the compound is not intended for human exposure and has not been evaluated in formal pharmacokinetic studies.
|
| Toxicity/Toxicokinetics |
3-Hydroxypyridine may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored in a cool, dry place away from light and moisture. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| References | |
| Additional Infomation |
3-Pyridinol is a monohydroxypyridine, meaning a compound in which the hydrogen atom at the 3-position of the pyridine ring is replaced by a hydroxyl group. It has been detected as a thermal degradation product of the smoke produced by burning the leaves of the Mexican psychoactive plant Salvia divinorum. 3-Hydroxypyridine has also been reported to be detected in peony (Paeonia lactiflora), Salvia divinorum, and chili pepper (Capsicum annuum var. annuum), but the relevant data are still unclear.
3-Hydroxypyridine is a compound that can be isolated from bamboo grass. It is an endogenous photosensitizer present in human skin that can mediate oxidative stress, proliferation inhibition, and apoptosis of skin cells through UVA/UVB excitation. 3-Hydroxypyridine derivatives are structural analogs of vitamin B6 and have diverse pharmacological properties, including antioxidant activity. It has not undergone clinical trials and is not approved as a pharmaceutical. |
| Molecular Formula |
C5H5NO
|
|---|---|
| Molecular Weight |
95.10
|
| Exact Mass |
95.037
|
| CAS # |
109-00-2
|
| Related CAS # |
3-Hydroxypyridine-d4
|
| PubChem CID |
7971
|
| Appearance |
White to off-white solid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
318.9±0.0 °C at 760 mmHg
|
| Melting Point |
125-128 °C(lit.)
|
| Flash Point |
146.6±20.4 °C
|
| Vapour Pressure |
0.0±0.7 mmHg at 25°C
|
| Index of Refraction |
1.560
|
| LogP |
0.64
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
56
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
OC1=CC=CN=C1
|
| InChi Key |
GRFNBEZIAWKNCO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C5H5NO/c7-5-2-1-3-6-4-5/h1-4,7H
|
| Chemical Name |
pyridin-3-ol
|
| Synonyms |
3-Hydroxypyridine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 110 mg/mL (1156.68 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.23 mg/mL (44.48 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 42.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.75 mg/mL (28.92 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.75 mg/mL (28.92 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 10.5152 mL | 52.5762 mL | 105.1525 mL | |
| 5 mM | 2.1030 mL | 10.5152 mL | 21.0305 mL | |
| 10 mM | 1.0515 mL | 5.2576 mL | 10.5152 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
